Background

This clinical trial enrolls patients with prostate cancer who have received radiation therapy as well as those with recurrent disease. Radiation destroys tumor cells, but a subset of patients may exhibit resistance to treatment. High‑resolution imaging techniques are being employed to understand the basis of this variability. The approach provides essential baseline data for developing personalized therapeutic strategies.

Study Design

Participants undergo a comprehensive assessment that includes an initial prostate MRI, with imaging changes monitored at six‑month intervals before and after therapy. Radiation is delivered according to current standard protocols. Patients with recurrence join the study after discussion of therapeutic options. This design reflects real‑world clinical practice, enhancing the external validity of the findings.

Expected Benefits

High‑resolution MRI enables precise discrimination between tumor and normal tissue, allowing objective assessment of radiation response. This contributes to elucidating mechanisms of radio‑resistance and provides a rationale for developing radiosensitizers or combination regimens. Moreover, patients benefit from early detection of recurrence, facilitating timely selection of appropriate salvage therapy.

Market and Clinical Implications

Prostate cancer is the most common malignancy among men, and radiation therapy is a standard treatment option. If successful, imaging‑based biomarkers are likely to be incorporated into clinical guidelines. This would generate new demand for medical imaging equipment manufacturers and radiation therapy device vendors, expanding the associated diagnostic‑service market.